Please login to the form below

Not currently logged in


This page shows the latest lirilumab news and features for those working in and with pharma, biotech and healthcare.

AZ swells immuno-oncology pipeline with Innate deal

AZ swells immuno-oncology pipeline with Innate deal

The AZ deal is a boost for Innate after it was forced to abandon BMS-partnered checkpoint inhibitor lirilumab last year on failed trials in head and neck cancer and acute

Latest news

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    Lirilumab combination fails to show additional benefit in SCCHN patients. French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another ... The biotech also said that a new look at data from

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...